George D. Demetri, MD, Dana-Farber Cancer Institute, Boston, Massachusetts
Susan Band Horwitz, PhD, Albert Einstein College of Medicine, Bronx, New York
Pasi A. Jänne, MD, PhD, Dana-Farber Cancer Institute, Boston, Massachusetts
Break
9:45-10 a.m.
Introduction to Cancer Medicine and Diagnostics (continued)
10-11:30 a.m.
Cancer imaging: The role of imaging in oncology
Lawrence H. Schwartz, MD, Columbia University Medical Center, New York, New York
EGFR mutant lung cancer: From clinic to bench to back to clinic
Pasi A. Jänne, MD, PhD, Dana-Farber Cancer Institute, Boston, Massachusetts
Panel Discussion and Questions: Personalized Cancer Medicine and What It Means in the Clinic
Buffet Lunch
11:30 a.m.-12:30 p.m.
Offsite Laboratory Visits
12:30-5 p.m.
Dana-Farber Cancer Institute
*Transportation will be provided.
Surgical Pathology Laboratory tour and discussion
Diagnostic Radiology Laboratory tour and discussion
*Workshop attendees visit both laboratories during the time allotted.
Group Buffet Dinner
5-6 p.m.
Study Design Track: Project Meeting #1
Those who are in the Project Meeting will miss the One-on-One Meetings.
5:45-7:15 p.m.
One-on-One Meetings ("Office Hours")
6-7 p.m.
How Treatment Decisions Are Made
7:15-8:15 p.m.
George D. Demetri, MD, Dana-Farber Cancer Institute, Boston, Massachusetts
Pasi A. Jänne, MD, PhD, Dana-Farber Cancer Institute, Boston, Massachusetts
Lynette M. Sholl, MD, Brigham and Women's Hospital, Boston, Massachusetts
Top of page
Tuesday, Nov. 6
Continental Breakfast
7-8 a.m.
The
Environment of Clinical Investigations
8-10:30 a.m.
Clinical research: An overview
Peter C. Adamson, MD, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
Human subjects considerations in translational research
Mark E. Robson, MD, Memorial Sloan Kettering Cancer Center, New York, New York
Protection of human research participants
Alison Bateman-House, NYU School of Medicine, New York, New York
Why quantitative reasoning is important in translational cancer research
Mimi Kim, Albert Einstein College of Medicine, New York, New York
Panel Discussion
Break / Group Photo
10:30-11:30 a.m.
Offsite IRB Observational Visit
11:30 a.m.-2 p.m.
Dana-Farber Cancer Institute
*Transportation will be provided.
Participants observe
a live Institutional Review Board (IRB) session in order to gain
insights into issues of protection of human subjects that are at the
heart of translational research. One to two weeks beforehand,
application titles will be shared with the attendees if possible.
Lunch / Overview of IRB
George D. Demetri, MD, Dana-Farber Cancer Institute, Boston, Massachusetts
Observation of Live IRB Session
Panel Discussion and Questions on Live IRB Session
Orientation / Questions for Cancer Patient Clinic Visits
2-2:30 p.m.
George D. Demetri, MD, Dana-Farber Cancer Institute, Boston, Massachusetts
Pasi A. Jänne, MD, PhD, Dana-Farber Cancer Institute, Boston, Massachusetts
Free Time
2:30-4 p.m.
Study Design Track: Project Meeting #2
3-4:30 p.m.
One-on-One Meetings (”Office Hours”)
4-5:30 p.m.
Group Buffet Dinner
5:30-6:30 p.m.
Small
Group Discussion Sessions with Clinician and Patient
6:30-8 p.m.
Each small group consists of a
clinician, a patient, and approximately 10-15 workshop attendees. This
provides a comfortable environment and encourages interaction. We ask
doctors to share their perspectives as clinicians and researchers and
patients to speak about whatever they feel most comfortable sharing
regarding their experiences as patients/clinical trial participants.
Top of page
Wednesday, Nov. 7
Continental Breakfast
7:45-8:45 a.m.
Offsite Patient Clinic Visits
8:45 a.m.-12 p.m.
Dana-Farber Cancer Institute
Massachusetts General Hospital
*Transportation will be provided.
Buffet Lunch
12-1 p.m.
The Research and Development Process
1-3:45 p.m.
Taxol, tubulin, and tumors: A story of drug development
Susan Band Horwitz, PhD, Albert Einstein Medical College, Bronx, New York
Developing new approaches to difficult drug cancer targets
Nathanael S. Gray, PhD, Dana-Farber Cancer Institute, Boston, Massachusetts
Additional speakers to be announced
Panel Discussion and Questions: Research and Development
Break
3:45-4:15 p.m.
Interactive Lab and Demo-cBioPortal: Cancer Genomics and Translational Research
4:15-6:15 p.m.
The cBioPortal for cancer genomics
Nikolaus Schultz, PhD, Memorial Sloan Kettering Cancer Center, New York, New York
Ethan Cerami, PhD, Dana-Farber Cancer Institute, Boston, Massachusetts
Evening on Own
6:15 p.m.-
Top of page
Thursday, Nov. 8
Continental Breakfast
7:45-8:45 a.m.
Offsite Patient Clinic Visits
8:45 a.m.-12 p.m.
Dana-Farber Cancer Institute
Massachusetts General Hospital
*Transportation will be provided.
Buffet Lunch
12-1 p.m.
Targeted Medicine
1-3:30 p.m.
Genomic analysis of cell-free plasma DNA
Geoffrey R. Oxnard, MD, Dana-Farber Cancer Institute, Boston, Massachusetts
Biomarkers and molecular diagnostics: The problem of patient selection
Maureen Cronin, PhD, Celgene Corporation, San Francisco, California
Additional speakers to be announced
Panel Discussion and Questions: Targeted Medicine
Break
3:30-4 p.m.
Panel Discussion on Entrepreneurship in Translational Research
4-5:30 p.m.
Deborah Dunsire, MD, XTuit Pharmaceuticals, Waltham, Massachusetts
Sangeeta N. Bhatia, MD, PhD, Massachusetts Institute of Technology, Cambridge, Massachusetts
Chi Van Dang, MD, PhD, Ludwig Institute for Cancer Research, New York, New York
Cigall Kadoch, PhD, Dana-Farber Cancer Institute, Boston, Massachusetts
Alexis Borisy, Third Rock Ventures, LLC, Boston, Massachusetts
Dinner
5:30-6:30 p.m.
Special Seminar and Group Discussion: Unleashing the Power of Immune System – Focus on Translational Immunology
6:30-8 p.m.
From basic science to cancer immunotherapy: T cell-mediated anti-tumor immunity
Kai W. Wucherpfennig, MD, PhD, Dana-Farber Cancer Institute, Boston, Massachusetts
Additional speaker to be announced
Top of page
Friday, Nov. 9
Continental Breakfast
7-8 a.m.
Translating Differently
8-10:45 a.m.
